SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-PositiveRecurrent or Metastatic Breast Cancer
Conditions
HER2-PositiveRecurrent or Metastatic Breast Cancer
Trial Timeline
Oct 16, 2023 → Oct 1, 2032
NCT ID
NCT06057610About SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection
SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for HER2-PositiveRecurrent or Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06057610. Target conditions include HER2-PositiveRecurrent or Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06057610 | Phase 3 | Active |